Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

4.04USD
1 Oct 2014
Price Change (% chg)

$-0.22 (-5.16%)
Prev Close
$4.26
Open
$4.26
Day's High
$4.26
Day's Low
$4.01
Volume
850,916
Avg. Vol
937,716
52-wk High
$7.82
52-wk Low
$4.01

OREX.OQ

Chart for OREX.OQ

About

Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the... (more)

Overall

Beta: 2.41
Market Cap (Mil.): $495.04
Shares Outstanding (Mil.): 122.53
Dividend: --
Yield (%): --

Financials

  OREX.OQ Industry Sector
P/E (TTM): -- 129.49 34.07
EPS (TTM): -0.83 -- --
ROI: -90.89 -1.76 17.40
ROE: -404.35 -6.56 18.25
Search Stocks

CORRECTED-Long-awaited diet pill gets U.S. approval

(Corrects paragraph 9 to say RS Investments, not RS Investments' value fund, holds a stake in Orexigen. A previous version was corrected to fix Daniel Lang's designation)

11 Sep 2014

MARKET PULSE-Bancorp, Biofuel, Boeing, Ocera, Orexigen

NOTE TO SUBSCRIBERS: Reuters is converting some short-form coverage of hot stocks, including Market Pulse, into the new Stocks Buzz product. From June 16, items that were previously published only as a compilation will be published as standalone items featuring the BUZZ tag. They will also be accessible via the STXBZ news code. A collated version will continue to appear on the WATCH/US named-item code under the headline "BUZZ-U.S. stocks on the move".

11 Jun 2014

MARKET PULSE-The Bancorp, Biofuel, Orexigen, Synaptics

NOTE TO SUBSCRIBERS: Reuters is converting some short-form coverage of hot stocks, including Market Pulse, into the new Stocks Buzz product. From June 16, items that were previously published only as a compilation will be published as standalone items featuring the BUZZ tag. They will also be accessible via the STXBZ news code. A collated version will continue to appear on the WATCH/US named-item code under the headline "BUZZ-U.S. stocks on the move".

11 Jun 2014

FDA delays decision on Orexigen's obesity drug by three months

- Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the company's shares down as much as 20 percent on Wednesday.

11 Jun 2014

UPDATE 2-FDA delays decision on Orexigen's obesity drug by 3 months

June 11 - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the company's shares down as much as 20 percent on Wednesday.

11 Jun 2014

US STOCKS-Futures point to lower open amid dearth of incentives

* Futures down: Dow 70 pts, S&P 8 pts, Nasdaq 15.5 pts (Adds World Bank forecast and Orexigen news)

11 Jun 2014

FDA delays decision on Orexigen's obesity drug by three months

June 11 - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its shares down about 12 percent in premarket trading.

11 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks